Summary: About 30% of people with major depression do not respond sufficiently to standard medications, psychotherapy, or other established treatments — a condition called treatment-resistant depression (TRD). Researchers are investigating deep brain stimulation (DBS) as a potential option for these patients, with clinical trials underway to test safety and long-term benefit.
DBS, an FDA-approved therapy for Parkinson’s disease and other movement disorders, works like a pacemaker for the brain: tiny electrodes deliver controlled electrical pulses to influence neural activity. Early clinical experience and ongoing trials, including the national TRANSCEND study and research at UT Southwestern (UTSW), suggest that targeting white matter pathways can help “unstick” brains stuck in prolonged depressive states, allowing gradual improvement in mood and function.
Key Facts
- The goal: unstick the brain: DBS for depression is not an instant mood booster. It aims to reduce biological barriers that maintain a depressed state so patients can reengage with daily life and psychotherapy.
- White matter vs. gray matter: Unlike DBS for movement disorders, which stimulates gray matter, DBS for depression targets white matter tracts — the communication highways linking mood and motivation centers. Effects tend to emerge over weeks to months rather than immediately.
- The TRANSCEND trial: UTSW is a recruiting site for this randomized, double-blind, placebo-controlled trial designed to objectively evaluate DBS for TRD. During the blinded phase, neither patients nor clinicians know who is receiving active stimulation.
- Who is considered: Typical candidates are adults with a history of severe, long-lasting depression who have not responded to multiple treatments (commonly four or more), and who meet strict safety and psychiatric criteria.
Source: UT Southwestern
Many people benefit from antidepressants and psychotherapy, but a significant minority do not.
For roughly a third of patients, depressive symptoms persist despite several evidence-based treatments. This treatment-resistant depression may stem from biological differences in brain circuitry, from intolerable side effects, or from barriers to adhering to treatment plans. Effective care for TRD often requires a multidisciplinary team that includes psychiatrists, neurosurgeons, and other specialists to tailor advanced options and ongoing management.
DBS is one of the advanced interventions being studied for TRD. While DBS is established and effective for movement disorders such as Parkinson’s disease, its use in depression remains investigational and is available only through research protocols.
How is “treatment-resistant depression” defined?
There is no single definition that captures every patient, but TRD is commonly used to describe depression that does not improve after adequate trials of at least two to three standard antidepressant medications. Clinical judgment matters: sleep, nutrition, medical conditions, social stressors, access to therapy, medication adherence, and other factors all influence treatment response. For people whose symptoms persist despite optimal care and adherence, advanced therapies such as ketamine, transcranial magnetic stimulation (TMS), electroconvulsive therapy (ECT), or experimental DBS may be considered.
- Sleep, diet, hydration and general health
- Medication adherence and correct dosing
- Work, family, and social stressors
- Access to and engagement with psychotherapy
- Other medical or psychiatric conditions
When these areas are optimized and depression still does not respond, clinicians and patients may explore other evidence-based options.
Common alternatives offered for TRD include:
- Ketamine or esketamine: Ketamine, given intravenously under close supervision, and intranasal esketamine can produce rapid antidepressant effects in some patients, including those with suicidal ideation.
- Transcranial magnetic stimulation (TMS): TMS uses focused magnetic pulses to modulate brain regions involved in mood. Typical courses involve daily sessions for several weeks and can significantly reduce symptoms for many patients.
- Electroconvulsive therapy (ECT): ECT remains a highly effective, evidence-based treatment for severe depression. It involves brief controlled seizures under anesthesia and is usually delivered two to three times per week for several weeks.
How does DBS work?
DBS systems consist of thin electrodes implanted in the brain and a small pulse generator implanted beneath the skin, often below the collarbone. The generator delivers continuous electrical stimulation tuned to the patient’s needs. Batteries may be rechargeable or nonrechargeable; rechargeable units are smaller and last longer but require periodic recharging, while nonrechargeable batteries are replaced by a short outpatient procedure after a few years.
Once activated, patients typically do not feel the stimulation. DBS is adjustable, reversible, and programmable: clinicians can modify settings or turn the device off, and the hardware can be removed if needed. DBS is well established for movement disorders, where benefits such as tremor reduction are often immediate. For depression, by contrast, benefits usually accrue more gradually because the therapy modulates communication pathways rather than directly driving neural firing.
How is DBS used to treat depression?
DBS for depression targets white matter circuits that connect brain regions involved in mood, motivation, and emotional regulation. The intent is to restore flexible communication among these regions so the brain can exit a locked depressive state. Stimulation levels and targets differ from movement disorder DBS, and clinical improvement typically develops over weeks to months rather than instantaneously.
The therapy is not intended to force happiness or alter core personality traits; rather, it aims to reduce biological barriers so patients can recover normal emotional range and reengage with therapy and activities that support recovery.
Patients who previously responded to ECT but then relapsed may be especially likely to benefit from DBS, since their brains have demonstrated the capacity to change with treatment.
How can I access DBS for depression?
DBS for depression is currently available only through clinical research. UT Southwestern runs its own DBS study and is recruiting for the TRANSCEND trial, a large randomized, double-blind study designed to rigorously assess safety and efficacy. These trials follow patients for at least a year to capture gradual improvements and long-term outcomes. In TRANSCEND, participants receive a nonrechargeable battery during the blinded phase to preserve masking; if appropriate, it can be exchanged for a rechargeable unit after the trial.
Earlier short trials yielded mixed results because both treated and sham groups reported improvements in the short term. Longer follow-up and refined trial designs now aim to determine whether sustained benefit is attributable to DBS. Some trial participants continued to improve over years of stimulation, and some experienced relapse when batteries were depleted, suggesting a treatment effect for at least a subgroup.
Who might be eligible for DBS clinical trials?
Eligibility criteria vary by study, but common requirements include:
- Diagnosis of major depressive disorder.
- Stable medication and therapy plans for at least four weeks before enrollment.
- Current major depressive episode longer than three months, or history of multiple episodes.
- Inadequate response to four or more established depression treatments.
- Not being pregnant and not at acute risk of suicide.
- No current or past history of psychosis.
Candidates continue their usual medications and psychotherapy during trials to keep other treatments stable while researchers assess DBS’s specific effects. Multidisciplinary psychiatric review and consensus among specialists are required before proceeding with implantation.
A hopeful future for depression care
If TRANSCEND and related trials demonstrate clear, sustained benefit, the evidence could support FDA approval for DBS in treatment-resistant depression. Regulatory timelines vary, but wider availability could follow within several years if trials are successful. DBS would join other advanced treatments to give carefully selected patients another option when conventional therapies fail.
There is no single cure for depression, and most people benefit from a combination of therapies. For those with severe, persistent symptoms, clinical trials and advanced treatments like DBS offer an opportunity to regain functioning and improve quality of life. If you or a loved one are struggling with TRD, discuss advanced options and trial opportunities with your mental health provider.
Key Questions Answered:
A: No. DBS is not a “joy button.” Its purpose is to reduce the biological obstacles that keep someone stuck in depression. Many patients say it helps them feel like themselves again, able to experience a normal range of emotions and reconnect with life.
A: Both involve electricity, but they work differently. ECT induces a brief controlled seizure under anesthesia over a series of treatments. DBS provides continuous, adjustable stimulation from an implanted device. Patients who previously responded to ECT but relapsed are often considered promising candidates for DBS.
A: The implanted device can be turned off or removed; the effects of stimulation are reversible. DBS modulates electrical signaling without destroying brain tissue, and adjustments can be made to the device settings based on clinical response.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Source journal paper reviewed in full by staff.
- Additional context and institutional perspective added by the editorial team.
About this neurotech and depression research news
Author: Frederick Hitti
Source: UT Southwestern
Contact: Frederick Hitti – UT Southwestern
Image: The image is credited to Neuroscience News